Celera sparks genomics sector
Investors responded favorably to the publication on Monday of the first drafts of the human genome by Celera (CRA) and the International Human Genome Consortium. The total market cap of the 10 genomic stocks tracked by BioCentury rose $724 million (6.2 percent)